
Diageo, Regencell Bioscience, and UP Fintech are the three Chinese stocks to watch today, according to MarketBeat’s stock screener tool. Chinese stocks are equity securities issued by companies headquartered in or deriving most of their revenue from mainland China that investors buy and sell to gain ownership and participate in corporate profits. They trade on venues such as the Shanghai and Shenzhen exchanges (A‑shares), the Hong Kong Stock Exchange (H‑shares) and overseas via ADRs or Cayman‑listed firms, and they carry specific regulatory, currency and geopolitical risks as well as growth opportunities for investors. These companies had the highest dollar trading volume of any Chinese stocks within the last several days.
Diageo (DEO)
Diageo plc, together with its subsidiaries, engages in the production, marketing, and sale of alcoholic beverages. The company offers scotch, gin, vodka, rum, raki, liqueur, wine, tequila, Chinese white spirits, cachaça, and brandy, as well as beer, including cider and flavored malt beverages. It also provides Chinese, Canadian, Irish, American, and Indian-Made Foreign Liquor whiskies, as well as flavored malt beverages, ready to drink, and non-alcoholic products.
Regencell Bioscience (RGC)
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder.
Read Our Latest Research Report on RGC
UP Fintech (TIGR)
UP Fintech Holding Limited provides online brokerage services focusing on Chinese investors. The company has developed a brokerage platform, which allows investor to trade stocks, options, warrants, and other financial instruments that can be accessed through its APP and website. It offers brokerage and value-added services, including investor education, community engagement, and IR platform services.
Read Our Latest Research Report on TIGR
Featured Articles
- MarketBeat’s Top Five Stocks to Own in January 2026
- Beyond Biotech—3 Healthcare Stocks for Growth-Minded Investors
- Procter & Gamble Confirms a Bottom—Time to Start Compounding?
- The Hot Dog Hedge: Smithfield Acquires Nathan’s Famous
- What’s the Best Way to Buy Gold in 2026?
- Is Abbott’s January Pullback a Good Time to Buy?
